UCB Pharma
UCB | Inspired by patients. Driven by science..
Launch date
Employees
Market cap
CAD46.4b
Enterprise valuation
CAD49.9b (Public information from Sep 2024)
Share price
€160.05 UCB.BR
Brussels Brussels-Capital (HQ)
Corporate Venture Fund: UCB Ventures
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.3b | 5.8b | 5.5b | 5.3b | 5.8b | 6.7b | 7.4b |
% growth | 9 % | 8 % | (5 %) | (5 %) | 10 % | 16 % | 11 % |
EBITDA | 1.4b | 1.6b | 1.3b | 1.3b | 1.4b | 2.1b | 2.5b |
% EBITDA margin | 26 % | 27 % | 23 % | 24 % | 24 % | 31 % | 33 % |
Profit | 732m | 1.1b | 418m | 343m | 418m | 882m | 1.4b |
% profit margin | 14 % | 18 % | 8 % | 7 % | 7 % | 13 % | 19 % |
EV / revenue | 3.3x | 3.4x | 2.9x | 3.3x | 5.7x | 4.8x | 4.1x |
EV / EBITDA | 12.3x | 12.8x | 12.6x | 13.5x | 23.7x | 15.5x | 12.4x |
R&D budget | 1.6b | 1.6b | 1.7b | 1.6b | - | - | - |
R&D % of revenue | 29 % | 28 % | 30 % | 31 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
$100m | Post IPO Equity | ||
* | €94.5m | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about UCB Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by UCB Pharma
EditACQUISITION by Biotie Therapies Jan 2011
ACQUISITION by UCB Pharma Jan 2022
exited
ACQUISITION by UCB Pharma Oct 2019
ACQUISITION by UCB Pharma Jun 2017
ACQUISITION by UCB Pharma Nov 2020